Ed Sitar
About Ed Sitar
Ed Sitar serves as the Chief Financial Officer at Variantyx and has a notable history of resolving patent matters and securing regulatory approvals in the medical device sector. With extensive experience in financial leadership across multiple companies, he has demonstrated strong fundraising capabilities and strategic financial management.
Work at Variantyx
Ed Sitar serves as the Chief Financial Officer at Variantyx, a position he has held since 2022. In this role, he has been instrumental in developing new pricing models that have secured and retained over $50 million in revenue. His work incorporates significant risk and gain-sharing elements, demonstrating his strategic approach to financial management.
Previous Experience in Finance
Prior to his role at Variantyx, Ed Sitar held several key financial positions. He was the Chief Financial Officer at Cancer Genetics, Inc. from 2014 to 2017, and at Ammon Analytical Laboratory from 2017 to 2018. He also served as the Acting Chief Financial Officer at CareDox, Inc. in 2019. His tenure at ActiveHealth Management as CFO from 2010 to 2012 further solidified his expertise in financial leadership.
Education and Expertise
Ed Sitar earned a Bachelor of Science degree in Accounting from the University of Scranton, completing his studies from 1978 to 1982. He also holds a CPA license in New Jersey, which underscores his professional qualifications in accountancy and finance. His educational background includes attendance at Saint Joseph High School and St. Mary's Plainfield.
Achievements in Fundraising and Cost Savings
Throughout his career, Ed Sitar has demonstrated strong fundraising capabilities, having raised over $150 million in capital through private and public equity and debt sources. He has also delivered significant savings to clients, achieving over $300 million through strategic customer acquisition and retention efforts, resulting in a return greater than 500%.
Leadership Roles and Contributions
In addition to his role at Variantyx, Ed Sitar serves as the Lead Independent Director and Audit Committee Chair at Timber Pharmaceuticals since 2020. He has participated in multiple acquisitions and joint venture arrangements, contributing to the growth and expansion strategies of the companies he has worked with.